GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » Short Percentage of Float

IDEAYA Biosciences (FRA:30J) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of IDEAYA Biosciences's Short Percentage of Float

For the Biotechnology subindustry, IDEAYA Biosciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Short Percentage of Float falls into.


;
;

IDEAYA Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » Short Percentage of Float
Comparable Companies
AGIO HRMY TVTX CGON ARQT IRON EWTX ARWR JANX VERA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
IDYA:USA
Address
5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Website
https://www.ideayabio.com
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

IDEAYA Biosciences Headlines

No Headlines